Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019041045) PROFILING AND TREATMENT OF HYPERMUTANT CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/041045 International Application No.: PCT/CA2018/051054
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
C12Q 1/6809 (2018.01) ,A61P 35/00 (2006.01) ,C12Q 1/6886 (2018.01)
[IPC code unknown for C12Q 1/6809]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
[IPC code unknown for C12Q 1/6886]
Applicants:
THE HOSPITAL FOR SICK CHILDREN [CA/CA]; 555 University Avenue Toronto, Ontario M5G 1X8, CA
Inventors:
TABORI, Uri; CA
SHLIEN, Adam; CA
Agent:
BOOCOCK, Graeme R.; CA
VICKERS, Mark F.; CA
DAMIANI, Michael; CA
EVENSON, Brandon; CA
FRITZ, Joachim T.; CA
WOOD, David; CA
ALLARD, Louis B.; CA
BEHMANN, Curtis B.; CA
DE KLEINE, Geoffrey; CA
HUNG, Shin; CA
KEELER, Todd; CA
MARSMAN, Kathleen E.; CA
NAUMAN, David A.; CA
PUNDSACK, Scott; CA
COGHLAN, Jeffrey; CA
GORDON, Jeff; CA
RAOUL, Jennifer; CA
SILVER, Gail C.; CA
SOJONKY, Andrew D.; CA
WEBB, Timothy; CA
ZIMMERMAN, Gord; CA
MUELLER-NEUHAUS, Jason R.; CA
Priority Data:
62/553,37501.09.2017US
Title (EN) PROFILING AND TREATMENT OF HYPERMUTANT CANCER
(FR) PROFILAGE ET TRAITEMENT D'UN CANCER HYPERMUTANT
Abstract:
(EN) There is provided a method of profiling a tumour, the method comprising determining a relative proportion for each of 96 mutation types, wherein the 96 mutation types are defined as the six possible sequence changes C>A, C>G, C>T, T>A, T>C, or T>G in the context of each of four possible nucleotides (A, C, G, or T) at the position immediately 5' to the mutation and each of four possible nucleotides at the position immediately 3' to the mutation; assigning the tumour, using the determined relative proportion for each of the 96 mutation types, to at least one of eight clusters defined herein; and determining at least one tumour characteristic based on the assignment to a cluster.
(FR) L'invention concerne un procédé de profilage d'une tumeur, le procédé consistant à déterminer une proportion relative de chacun des 96 types de mutation, les 96 types de mutation étant définis comme étant les six changements de séquence possibles C>A, C>G, C>T, T>A, T>C ou T>G dans le contexte de chacun des quatre nucléotides possibles (A, C, G ou T) se situant dans la position immédiatement 5' par rapport à la mutation, et chacun des quatre nucléotides possibles se situant dans la position immédiatement 3' par rapport à la mutation ; affecter la tumeur, à l'aide de la proportion relative déterminée pour chacun des 96 types de mutation, à au moins un de huit groupes définis dans la description ; et déterminer au moins une caractéristique de tumeur sur la base de l'affectation à un groupe.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)